Tourette Syndrome Mental and Behavioural Disorders Tic disorders
Conditions
Interventions
Patients will be randomsied to the following medication:
1. Magnesium pidolate 0.5 mEq/Kg/day, divided to be taken twice daily. This should not be taken in conjunction with calcium or dairy products.
Sponsors
The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 7 - 14 years, either sex. This is the age bracket during which the natural course of the illness is most exacerbated. Before the age of 7 years, the tics may not yet have appeared (this generally occurs at the age of 5 - 7 years). After 14 years, symptoms tend to stabilise. 2. Informed consent of the child's parents or guardians, and reasoned agreement with the child 3. Clinical diagnosis of TS, according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria 4. Score of 40 or more on the YGTSS
Exclusion criteria
Exclusion criteria: 1. Severe attention deficit hyperactivity disorder (ADHD) or obsessive compulsive disorder (OCD), not clinically controlled 2. Autism 3. Unrelated depression 4. Allergy to acetylsalicylic acid (due to the excipients used)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical diagnosis of TS will be confirmed, and the YGTSS score ascertained, so that the patient may be included in the study and any subsequent fall in the global score recorded (at t0 ,t1, t2, t3 and t4). | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolic changes in baseline and post-treatment PET will be recorded. | — |
Countries
Spain
Outcome results
None listed